Home » Analyst Articles – US

TreeHouse Foods (THS) Upgraded by Zacks Investment Research to “Buy”

TreeHouse Foods (THS) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of TreeHouse Foods (NYSE:THS) from a hold rating to a buy rating in a research report released on Tuesday. Zacks Investment Research currently has $54.00 price target on the stock. According... 
Zacks Investment Research Upgrades Synthetic Biologics (SYN) to “Buy”

Zacks Investment Research Upgrades Synthetic Biologics (SYN) to “Buy”

Zacks Investment Research upgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a hold rating to a buy rating in a research report released on Tuesday morning. The firm currently has $0.25 target price on the stock. According... 
Purple Innovation (PRPL) Upgraded to Buy at Zacks Investment Research

Purple Innovation (PRPL) Upgraded to Buy at Zacks Investment Research

Purple Innovation (NASDAQ:PRPL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm currently has a $6.50 target price... 
ORION OYJ/ADR (ORINY) Upgraded to “Buy” by Zacks Investment Research

ORION OYJ/ADR (ORINY) Upgraded to “Buy” by Zacks Investment Research

ORION OYJ/ADR (OTCMKTS:ORINY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $20.00 target price on the stock.... 
Vectrus (VEC) Downgraded to “Hold” at ValuEngine

Vectrus (VEC) Downgraded to “Hold” at ValuEngine

ValuEngine cut shares of Vectrus (NYSE:VEC) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning. Several other research analysts also recently issued reports on the stock. Zacks Investment Research... 
Flex Pharma (FLKS) Lowered to Sell at Zacks Investment Research

Flex Pharma (FLKS) Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Flex Pharma (NASDAQ:FLKS) from a buy rating to a sell rating in a research report report published on Tuesday. According to Zacks, “Flex Pharma, Inc. is a biotechnology company. The Company... 
HENNES & MAURIT/ADR (HNNMY) Upgraded to Hold at Zacks Investment Research

HENNES & MAURIT/ADR (HNNMY) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of HENNES & MAURIT/ADR (OTCMKTS:HNNMY) from a sell rating to a hold rating in a research report sent to investors on Tuesday. According to Zacks, “H & M Hennes & Mauritz... 
BARLOWORLD Ltd/ADR (BRRAY) Upgraded by Zacks Investment Research to Hold

BARLOWORLD Ltd/ADR (BRRAY) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of BARLOWORLD Ltd/ADR (OTCMKTS:BRRAY) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning. According to Zacks, “Barlow LTD is an international... 
ARBOR Rlty Tr I/SH (ABR) Rating Reiterated by JMP Securities

ARBOR Rlty Tr I/SH (ABR) Rating Reiterated by JMP Securities

ARBOR Rlty Tr I/SH (NYSE:ABR)‘s stock had its “buy” rating restated by JMP Securities in a research note issued on Wednesday. They currently have a $12.00 target price on the real estate investment trust’s stock.... 
Synergy Pharmaceuticals (SGYP) Stock Rating Upgraded by Zacks Investment Research

Synergy Pharmaceuticals (SGYP) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Synergy Pharmaceuticals (NASDAQ:SGYP) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $2.00 target price on the biopharmaceutical... 
Alexion Pharmaceuticals (ALXN) Upgraded to “Buy” at Zacks Investment Research

Alexion Pharmaceuticals (ALXN) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a hold rating to a buy rating in a report published on Tuesday. Zacks Investment Research currently has $133.00 price objective on the biopharmaceutical... 
H & R Block (HRB) Upgraded at Zacks Investment Research

H & R Block (HRB) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of H & R Block (NYSE:HRB) from a sell rating to a hold rating in a report released on Tuesday. According to Zacks, “H&R Block is focusing on its core tax business and has divested... 
Zacks Investment Research Lowers Sunesis Pharmaceuticals (SNSS) to Hold

Zacks Investment Research Lowers Sunesis Pharmaceuticals (SNSS) to Hold

Zacks Investment Research lowered shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a buy rating to a hold rating in a research note released on Tuesday. According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical... 
Tilray (TLRY) Earns Buy Rating from Analysts at Roth Capital

Tilray (TLRY) Earns Buy Rating from Analysts at Roth Capital

Roth Capital initiated coverage on shares of Tilray (NASDAQ:TLRY) in a research report report published on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $35.00 price objective on the stock. Separately, Cowen... 
Royal Bank of Canada (RY) Cut to Sell at Zacks Investment Research

Royal Bank of Canada (RY) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Royal Bank of Canada (NYSE:RY) (TSE:RY) from a hold rating to a sell rating in a research report released on Tuesday. According to Zacks, “ROYAL BANK of Canada operate under the... 
Construction Partners (ROAD) Lowered to “Sell” at Zacks Investment Research

Construction Partners (ROAD) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Construction Partners (NASDAQ:ROAD) from a hold rating to a sell rating in a report published on Tuesday. According to Zacks, “Construction Partners Inc. is an infrastructure and road... 
Zacks Investment Research Upgrades Quidel (QDEL) to Strong-Buy

Zacks Investment Research Upgrades Quidel (QDEL) to Strong-Buy

Zacks Investment Research upgraded shares of Quidel (NASDAQ:QDEL) from a hold rating to a strong-buy rating in a research note published on Tuesday. They currently have $80.00 price target on the stock. According to Zacks, “Quidel... 
Axcelis Technologies (ACLS) Cut to Sell at ValuEngine

Axcelis Technologies (ACLS) Cut to Sell at ValuEngine

Axcelis Technologies (NASDAQ:ACLS) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. Several other equities analysts also recently... 
Aptose Biosciences (APTO) Upgraded to Hold by Zacks Investment Research

Aptose Biosciences (APTO) Upgraded to Hold by Zacks Investment Research

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday. According to Zacks, “Aptose Biosciences... 
Apple (AAPL) Rating Reiterated by Robert W. Baird

Apple (AAPL) Rating Reiterated by Robert W. Baird

Apple (NASDAQ:AAPL)‘s stock had its “buy” rating restated by stock analysts at Robert W. Baird in a report issued on Monday. They currently have a $230.00 price target on the iPhone maker’s stock. Robert W.... 
Rollins (ROL) Earns Hold Rating from Stifel Nicolaus

Rollins (ROL) Earns Hold Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their hold rating on shares of Rollins (NYSE:ROL) in a research note issued to investors on Sunday morning, Marketbeat reports. The brokerage currently has a $55.00 price objective on the business services... 
China Petroleum & Chemical (SNP) Cut to Hold at Zacks Investment Research

China Petroleum & Chemical (SNP) Cut to Hold at Zacks Investment Research

China Petroleum & Chemical (NYSE:SNP) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday. According to Zacks, “We appreciate... 
Zacks Investment Research Downgrades Axovant Sciences (AXON) to Sell

Zacks Investment Research Downgrades Axovant Sciences (AXON) to Sell

Axovant Sciences (NASDAQ:AXON) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday. According to Zacks, “Axovant Sciences Ltd. is a... 
Determine (DTRM) PT Lowered to $3.00

Determine (DTRM) PT Lowered to $3.00

Determine (NASDAQ:DTRM) had its price objective reduced by stock analysts at Needham & Company LLC to $3.00 in a note issued to investors on Monday, The Fly reports. The brokerage currently has a “buy” rating on the... 
Zacks Investment Research Downgrades Coherus Biosciences (CHRS) to Sell

Zacks Investment Research Downgrades Coherus Biosciences (CHRS) to Sell

Coherus Biosciences (NASDAQ:CHRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday. According to Zacks, “Coherus Biosciences, Inc. is a... 
Bancolombia (CIB) Downgraded by Zacks Investment Research to Sell

Bancolombia (CIB) Downgraded by Zacks Investment Research to Sell

Bancolombia (NYSE:CIB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday. According to Zacks, “BanColombia is Colombia’s largest bank... 
Compass Point Reiterates “$6.00” Price Target for Medley Management (MDLY)

Compass Point Reiterates “$6.00” Price Target for Medley Management (MDLY)

Compass Point set a $6.00 price target on Medley Management (NYSE:MDLY) in a research report sent to investors on Sunday. The firm currently has a hold rating on the asset manager’s stock. Separately, ValuEngine cut shares of... 
Raymond James Reiterates Buy Rating for Genesis Energy, L.P.  common stock (GEL)

Raymond James Reiterates Buy Rating for Genesis Energy, L.P. common stock (GEL)

Genesis Energy, L.P. common stock (NYSE:GEL)‘s stock had its “buy” rating reiterated by research analysts at Raymond James in a research report issued on Monday. The analysts wrote, “We are reducing our estimates... 
Zacks Investment Research Downgrades Curtiss-Wright (CW) to Hold

Zacks Investment Research Downgrades Curtiss-Wright (CW) to Hold

Curtiss-Wright (NYSE:CW) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday. According to Zacks, “Curtiss-Wright ended second quarter of 2018... 
ValuEngine Upgrades Hydrogenics (HYGS) to “Sell”

ValuEngine Upgrades Hydrogenics (HYGS) to “Sell”

Hydrogenics (NASDAQ:HYGS) (TSE:HYG) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Monday. Several other equities research analysts have... 
Freshpet (FRPT) Given New $32.00 Price Target at Credit Suisse Group

Freshpet (FRPT) Given New $32.00 Price Target at Credit Suisse Group

Freshpet (NASDAQ:FRPT) had its target price hoisted by stock analysts at Credit Suisse Group from $26.00 to $32.00 in a research report issued to clients and investors on Monday. The brokerage currently has a “hold” rating... 
Netflix (NFLX) Rating Reiterated by Robert W. Baird

Netflix (NFLX) Rating Reiterated by Robert W. Baird

Netflix (NASDAQ:NFLX)‘s stock had its “neutral” rating restated by investment analysts at Robert W. Baird in a research report issued on Monday. They presently have a $370.00 price target on the Internet television... 
Portola Pharmaceuticals (PTLA) Downgraded by ValuEngine

Portola Pharmaceuticals (PTLA) Downgraded by ValuEngine

Portola Pharmaceuticals (NASDAQ:PTLA) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday. PTLA has been the subject of a number... 
VF (VFC) Earns “Buy” Rating from Guggenheim

VF (VFC) Earns “Buy” Rating from Guggenheim

VF (NYSE:VFC)‘s stock had its “buy” rating restated by stock analysts at Guggenheim in a report released on Monday. They presently have a $105.00 price target on the textile maker’s stock. Guggenheim’s... 
ValuEngine Downgrades Noble Midstream Partners (NBLX) to Sell

ValuEngine Downgrades Noble Midstream Partners (NBLX) to Sell

Noble Midstream Partners (NYSE:NBLX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday. Several other analysts have also... 
Dycom Industries (DY) Rating Lowered to Strong Sell at ValuEngine

Dycom Industries (DY) Rating Lowered to Strong Sell at ValuEngine

Dycom Industries (NYSE:DY) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Monday. A number of other equities research... 
Aptevo Therapeutics (APVO) Upgraded to Buy at ValuEngine

Aptevo Therapeutics (APVO) Upgraded to Buy at ValuEngine

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday. Several other analysts also recently weighed... 
Dycom Industries (DY) Rating Lowered to Strong Sell at ValuEngine

Dycom Industries (DY) Rating Lowered to Strong Sell at ValuEngine

Dycom Industries (NYSE:DY) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Monday. A number of other equities research... 
Aptevo Therapeutics (APVO) Upgraded to Buy at ValuEngine

Aptevo Therapeutics (APVO) Upgraded to Buy at ValuEngine

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday. Several other analysts also recently weighed... 
Tecnoglass (TGLS) Lifted to Buy at ValuEngine

Tecnoglass (TGLS) Lifted to Buy at ValuEngine

Tecnoglass (NASDAQ:TGLS) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday. Several other equities analysts have also recently issued... 
Arrowhead Pharmaceuticals (ARWR) Given Buy Rating at Chardan Capital

Arrowhead Pharmaceuticals (ARWR) Given Buy Rating at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Monday. They currently have a $17.50 price objective on the biotechnology... 
Akamai Technologies (AKAM) Given “Neutral” Rating at Credit Suisse Group

Akamai Technologies (AKAM) Given “Neutral” Rating at Credit Suisse Group

Akamai Technologies (NASDAQ:AKAM)‘s stock had its “neutral” rating restated by investment analysts at Credit Suisse Group in a research report issued to clients and investors on Monday, MarketBeat reports. They currently... 
HC Wainwright Reiterates “Buy” Rating for Sorrento Therapeutics (SRNE)

HC Wainwright Reiterates “Buy” Rating for Sorrento Therapeutics (SRNE)

Sorrento Therapeutics (NASDAQ:SRNE)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Monday. They currently have a $40.00 price objective on the... 
Avaya (AVYA) Stock Rating Upgraded by Zacks Investment Research

Avaya (AVYA) Stock Rating Upgraded by Zacks Investment Research

Avaya (NYSE:AVYA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The brokerage presently has a $24.00 price target on the stock. Zacks Investment... 
First Majestic Silver (AG) Downgraded to Sell at ValuEngine

First Majestic Silver (AG) Downgraded to Sell at ValuEngine

First Majestic Silver (NYSE:AG) (TSE:FR) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Monday. Several other equities research analysts also... 
BRT Apartments (BRT) Downgraded by Zacks Investment Research

BRT Apartments (BRT) Downgraded by Zacks Investment Research

BRT Apartments (NYSE:BRT) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report issued on Monday. According to Zacks, “BRT is a real estate investment... 
ChemoCentryx’s (CCXI) “Buy” Rating Reiterated at HC Wainwright

ChemoCentryx’s (CCXI) “Buy” Rating Reiterated at HC Wainwright

ChemoCentryx (NASDAQ:CCXI)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Monday. They currently have a $20.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s... 
Cowen Begins Coverage on Tilray (TLRY)

Cowen Begins Coverage on Tilray (TLRY)

Investment analysts at Cowen assumed coverage on shares of Tilray (NASDAQ:TLRY) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $34.00 price target on the stock.... 
Wedbush Increases Brunswick (BC) Price Target to $77.00

Wedbush Increases Brunswick (BC) Price Target to $77.00

Brunswick (NYSE:BC) had its target price hoisted by research analysts at Wedbush from $70.00 to $77.00 in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm currently has an “outperform”... 
Nextdecade (NEXT) Given a $8.00 Price Target at Stifel Nicolaus

Nextdecade (NEXT) Given a $8.00 Price Target at Stifel Nicolaus

Stifel Nicolaus set a $8.00 price objective on Nextdecade (NASDAQ:NEXT) in a report released on Saturday. The brokerage currently has a hold rating on the stock. A number of other equities research analysts have also recently commented...